Abciximab
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00054 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 12 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | primary release disorder of platelets | KG + DL |
| 2 | Glanzmann thrombasthenia | KG + DL |
| 3 | pseudo-von Willebrand disease | KG + DL |
| 4 | hemorrhagic disorder due to a constitutional thrombocytopenia | KG + DL |
| 5 | bleeding diathesis due to a collagen receptor defect | KG + DL |
| 6 | Scott syndrome | KG + DL |
| 7 | fetal and neonatal alloimmune thrombocytopenia | KG + DL |
| 8 | Ledderhose disease | KG + DL |
| 9 | platelet-type bleeding disorder | KG + DL |
| 10 | penile fibromatosis | KG + DL |
| 11 | infantile digital fibromatosis | KG + DL |
| 12 | severe nonproliferative diabetic retinopathy | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.